Skip to main content

Table 4 Seroconversion rates (percentage of subjects with seroconversiona or a significant increase in HI titresb in subjects without pre-vaccination immunoprotection)

From: Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects

 

Seroconversion rates, %

Viral strain

Sub/MF59™

Subunit

A/H1N1 c

83.3

80.0

A/H3N2 d

85.1*

66.2

B e

33.4

25.8

  1. aSeroconversion is defined as negative pre-vaccination serum (i.e. haemagglutinin inhibition [HI] titre <1:10) and post-vaccination HI titre ≥ 1:40; bSignificant increase is defined as ≥ 4-fold increase from non-negative (≥ 1:10) pre-vaccination HI titre; cNumber of subjects: Sub/MF59™, 6; Subunit, 5; dNumber of subjects: Sub/MF59™, 288; Subunit, 152; eNumber of subjects: Sub/MF59™, 359; Subunit, 183
  2. *P < 0.001 versus the Subunit group
  3. Sub/MF59™, MF59™-adjuvanted subunit influenza vaccine; Subunit, non-adjuvanted subunit influenza vaccine
Back to article page

Immunity & Ageing

ISSN: 1742-4933

Contact us